Evidence map›Paper›PMID 37197601›Full record

SynthesisInternational journal of chronic obstructive pulmonary disease2023

NT-proBNP in Different Patient Groups of COPD: A Systematic Review and Meta-Analysis.

Xiaojie Su, Ting Lei, Haichuan Yu, Lu Zhang, Zhouzhou Feng, Tiankui Shuai, Hong Guo, Jian Liu

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of chronic obstructive pulmonary disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
9.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Biomarkers in COPD-Associated PH/CCP: Circulating Molecules and Cell-Intrinsic Marker.International journal of chronic obstructive pulmonary disease · 2025
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xiaojie SuThe First Clinical Medical College of Lanzhou University, Lanzhou City, Gansu Province, People's Republic of China.
Ting LeiThe First Clinical Medical College of Lanzhou University, Lanzhou City, Gansu Province, People's Republic of China.
Haichuan YuThe First Clinical Medical College of Lanzhou University, Lanzhou City, Gansu Province, People's Republic of China.ORCID 0000-0002-4231-2542
Lu ZhangThe First Clinical Medical College of Lanzhou University, Lanzhou City, Gansu Province, People's Republic of China.
Zhouzhou FengThe First Clinical Medical College of Lanzhou University, Lanzhou City, Gansu Province, People's Republic of China.
Tiankui ShuaiThe First Clinical Medical College of Lanzhou University, Lanzhou City, Gansu Province, People's Republic of China.
Hong GuoThe First Clinical Medical College of Lanzhou University, Lanzhou City, Gansu Province, People's Republic of China.
Jian LiuThe First Clinical Medical College of Lanzhou University, Lanzhou City, Gansu Province, People's Republic of China.ORCID 0000-0002-1825-571X
Lanzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: NT-proBNP, a peptide biomarker synthesized and secreted by cardiomyocytes in response to cardiac load, has gained attention in recent years for its potential role in respiratory diseases. Chronic Obstructive Pulmonary Disease (COPD), a chronic and progressive inflammatory condition affecting the respiratory system, is frequently associated with comorbidities involving the cardiovascular system. Consequently, the aim of this systematic review and meta-analysis was to evaluate the variations in NT-proBNP levels across distinct patient groups with COPD and establish a foundation for future investigations into the precise clinical significance of NT-proBNP in COPD. Methods: The search databases for this study were conducted in PubMed, Excerpt Medica database (Embase), Web of Science (WOS), and Cochrane Library databases. Databases were searched for studies on the predictive value of NT-proBNP in adult COPD patients. Results: A total of 29 studies (8534 participants) were included. Patients with stable COPD exhibit elevated levels of NT-proBNP [standardized mean difference(SMD) [95CI%]=0.51 [0.13,0.89]; Conclusion: NT-proBNP, a biomarker commonly used in clinical practice to evaluate cardiovascular disease, demonstrates significant variations in different stages of COPD and during the progression of the disease. The fluctuations in NT-proBNP levels could be indicative of the severity of pulmonary hypoxia and inflammation and cardiovascular stress among COPD patients. Therefore, assessing NT-proBNP levels in COPD patients can aid in making informed clinical decisions.

Indexed as

Pulmonary Disease, Chronic ObstructiveAdultBiomarkersHumansLungNatriuretic Peptide, BrainPeptide FragmentsBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)acute exacerbation of chronic obstructive pulmonary diseaseamino-terminal pro-brain natriuretic peptidechronic heart failurechronic obstructive pulmonary diseasemeta-analysis

Identifiers

PMID37197601
PMCPMC10183357
OpenAlexW4377011880

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.